U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H22I3N3O8
Molecular Weight 777.086
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IOPAMIDOL

SMILES

C[C@@]([H])(C(=Nc1c(c(c(c(c1I)C(=NC(CO)CO)O)I)C(=NC(CO)CO)O)I)O)O

InChI

InChIKey=XQZXYNRDCRIARQ-LURJTMIESA-N
InChI=1S/C17H22I3N3O8/c1-6(28)15(29)23-14-12(19)9(16(30)21-7(2-24)3-25)11(18)10(13(14)20)17(31)22-8(4-26)5-27/h6-8,24-28H,2-5H2,1H3,(H,21,30)(H,22,31)(H,23,29)/t6-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae8c18c9-3e7d-4515-b980-120025a88fc1 http://www.rxlist.com/isovue-drug.htm

Iopamidol is a nonionic, low-osmolar iodinated contrast agent. Iopamidol is indicated for angiography, pediatric angiocardiography, selective visceral arteriography and aortography, peripheral venography, and adult and pediatric intravenous excretory urography and intravenous adult and pediatric contrast enhancement of computed tomographic. Renal toxicity has been reported in a few patients with liver dysfunction who were given oral cholecystographic agents followed by intravascular contrast agents. Intravascular injection of contrast media is frequently associated with the sensation of warmth and pain especially in peripheral arteriography and venography. In angiocardiography the adverse reactions are: hot flashes, angina pectoris, flushing, bradycardia, hypotension, hives.

CNS Activity

Curator's Comment:: Animal studies indicate that iopamidol does not cross the blood-brain barrier to any significant extent following intravascular administration. http://www.ncbi.nlm.nih.gov/pubmed/3281839

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
ISOVUE-M 300

Approved Use

ISOVUE-M (lopamidol Injection) is indicated for intrathecal administration in adult neuroradiology including myelography (lumbar, thoracic, cervical, total columnar), and for contrast enhancement of computed tomographic (CECT) cisternography and ventriculography. ISOVUE-M 200 (lopamidol Injection) is indicated for thoraco-lumbar myelography in children over the age of two years.

Launch Date

5.04835211E11
Diagnostic
ISOVUE-M 300

Approved Use

ISOVUE-M (lopamidol Injection) is indicated for intrathecal administration in adult neuroradiology including myelography (lumbar, thoracic, cervical, total columnar), and for contrast enhancement of computed tomographic (CECT) cisternography and ventriculography. ISOVUE-M 200 (lopamidol Injection) is indicated for thoraco-lumbar myelography in children over the age of two years.

Launch Date

5.04835211E11
Diagnostic
ISOVUE-M 300

Approved Use

ISOVUE-M (lopamidol Injection) is indicated for intrathecal administration in adult neuroradiology including myelography (lumbar, thoracic, cervical, total columnar), and for contrast enhancement of computed tomographic (CECT) cisternography and ventriculography. ISOVUE-M 200 (lopamidol Injection) is indicated for thoraco-lumbar myelography in children over the age of two years.

Launch Date

5.04835211E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
112.7 μg/mL
15 mL single, intrathecal
dose: 15 mL
route of administration: Intrathecal
experiment type: SINGLE
co-administered:
IOPAMIDOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
931 μg × h/mL
15 mL single, intrathecal
dose: 15 mL
route of administration: Intrathecal
experiment type: SINGLE
co-administered:
IOPAMIDOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
single, intravenous
IOPAMIDOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
100%
IOPAMIDOL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
61 % single, intravenous
Dose: 61 %
Route: intravenous
Route: single
Dose: 61 %
Sources:
unhealthy, 21 years
n = 1
Health Status: unhealthy
Condition: disseminated lupus erythematosus manifested mainly by lupus nephritis, computed tomography
Age Group: 21 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Hepatotoxicity...
AEs leading to
discontinuation/dose reduction:
Hepatotoxicity (1 patient)
Sources:
612 mg/mL single, intrathecal
Dose: 612 mg/mL
Route: intrathecal
Route: single
Dose: 612 mg/mL
Sources:
unknown, 45 years
n = 1
Health Status: unknown
Condition: cervical myelography
Age Group: 45 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Generalized tonic-clonic seizure...
AEs leading to
discontinuation/dose reduction:
Generalized tonic-clonic seizure (1 patient)
Sources:
54250 mg single, intravenous
Dose: 54250 mg
Route: intravenous
Route: single
Dose: 54250 mg
Sources:
unknown, adult and children
n = 2074
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 2074
Sources:
Other AEs: Extravasation...
Other AEs:
Extravasation (18 patients)
Sources:
62775 mg single, intravenous
Dose: 62775 mg
Route: intravenous
Route: single
Dose: 62775 mg
Sources:
unknown, adult and children
n = 1851
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 1851
Sources:
Other AEs: Extravasation...
Other AEs:
Extravasation (5 patients)
Sources:
68544 mg single, intravenous
Dose: 68544 mg
Route: intravenous
Route: single
Dose: 68544 mg
Sources:
unknown, adult and children
n = 10064
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 10064
Sources:
Other AEs: Extravasation...
Other AEs:
Extravasation (23 patients)
Sources:
69768 mg single, intravenous
Dose: 69768 mg
Route: intravenous
Route: single
Dose: 69768 mg
Sources:
unknown, adult and children
n = 10831
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 10831
Sources:
Other AEs: Extravasation...
Other AEs:
Extravasation (32 patients)
Sources:
83700 mg single, intravenous
Dose: 83700 mg
Route: intravenous
Route: single
Dose: 83700 mg
Sources:
unknown, adult and children
n = 1851
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 1851
Sources:
Other AEs: Allergic reaction...
Other AEs:
Allergic reaction (3 patients)
Sources:
87516 mg single, intravenous
Dose: 87516 mg
Route: intravenous
Route: single
Dose: 87516 mg
Sources:
unknown, adult and children
n = 10064
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 10064
Sources:
Other AEs: Allergic reaction...
Other AEs:
Allergic reaction (46 patients)
Sources:
88740 mg single, intravenous
Dose: 88740 mg
Route: intravenous
Route: single
Dose: 88740 mg
Sources:
unknown, adult and children
n = 10831
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 10831
Sources:
Other AEs: Allergic reaction...
Other AEs:
Allergic reaction (42 patients)
Sources:
612 mg/mL single, intravenous
Dose: 612 mg/mL
Route: intravenous
Route: single
Dose: 612 mg/mL
Sources:
unknown, adult and children
n = 10064
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 10064
Sources:
Other AEs: Adverse event...
Other AEs:
Adverse event (69 patients)
Sources:
612 mg/mL single, intravenous
Dose: 612 mg/mL
Route: intravenous
Route: single
Dose: 612 mg/mL
Sources:
unknown, adult and children
n = 10831
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 10831
Sources:
Other AEs: Adverse event...
Other AEs:
Adverse event (74 patients)
Sources:
61225 mg/mL single, intravenous
Dose: 61225 mg/mL
Route: intravenous
Route: single
Dose: 61225 mg/mL
Sources:
unknown, adult and children
n = 2074
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 2074
Sources:
Other AEs: Allergic reaction...
Other AEs:
Allergic reaction (8 patients)
Sources:
775 mg/mL single, intravenous
Dose: 775 mg/mL
Route: intravenous
Route: single
Dose: 775 mg/mL
Sources:
unknown, adult and children
n = 1851
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 1851
Sources:
Other AEs: Adverse event...
Other AEs:
Adverse event (8 patients)
Sources:
775 mg/mL single, intravenous
Dose: 775 mg/mL
Route: intravenous
Route: single
Dose: 775 mg/mL
Sources:
unknown, adult and children
n = 2074
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 2074
Sources:
Other AEs: Adverse event...
Other AEs:
Adverse event (26 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hepatotoxicity 1 patient
Disc. AE
61 % single, intravenous
Dose: 61 %
Route: intravenous
Route: single
Dose: 61 %
Sources:
unhealthy, 21 years
n = 1
Health Status: unhealthy
Condition: disseminated lupus erythematosus manifested mainly by lupus nephritis, computed tomography
Age Group: 21 years
Sex: F
Population Size: 1
Sources:
Generalized tonic-clonic seizure 1 patient
Disc. AE
612 mg/mL single, intrathecal
Dose: 612 mg/mL
Route: intrathecal
Route: single
Dose: 612 mg/mL
Sources:
unknown, 45 years
n = 1
Health Status: unknown
Condition: cervical myelography
Age Group: 45 years
Sex: M
Population Size: 1
Sources:
Extravasation 18 patients
54250 mg single, intravenous
Dose: 54250 mg
Route: intravenous
Route: single
Dose: 54250 mg
Sources:
unknown, adult and children
n = 2074
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 2074
Sources:
Extravasation 5 patients
62775 mg single, intravenous
Dose: 62775 mg
Route: intravenous
Route: single
Dose: 62775 mg
Sources:
unknown, adult and children
n = 1851
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 1851
Sources:
Extravasation 23 patients
68544 mg single, intravenous
Dose: 68544 mg
Route: intravenous
Route: single
Dose: 68544 mg
Sources:
unknown, adult and children
n = 10064
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 10064
Sources:
Extravasation 32 patients
69768 mg single, intravenous
Dose: 69768 mg
Route: intravenous
Route: single
Dose: 69768 mg
Sources:
unknown, adult and children
n = 10831
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 10831
Sources:
Allergic reaction 3 patients
83700 mg single, intravenous
Dose: 83700 mg
Route: intravenous
Route: single
Dose: 83700 mg
Sources:
unknown, adult and children
n = 1851
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 1851
Sources:
Allergic reaction 46 patients
87516 mg single, intravenous
Dose: 87516 mg
Route: intravenous
Route: single
Dose: 87516 mg
Sources:
unknown, adult and children
n = 10064
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 10064
Sources:
Allergic reaction 42 patients
88740 mg single, intravenous
Dose: 88740 mg
Route: intravenous
Route: single
Dose: 88740 mg
Sources:
unknown, adult and children
n = 10831
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 10831
Sources:
Adverse event 69 patients
612 mg/mL single, intravenous
Dose: 612 mg/mL
Route: intravenous
Route: single
Dose: 612 mg/mL
Sources:
unknown, adult and children
n = 10064
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 10064
Sources:
Adverse event 74 patients
612 mg/mL single, intravenous
Dose: 612 mg/mL
Route: intravenous
Route: single
Dose: 612 mg/mL
Sources:
unknown, adult and children
n = 10831
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 10831
Sources:
Allergic reaction 8 patients
61225 mg/mL single, intravenous
Dose: 61225 mg/mL
Route: intravenous
Route: single
Dose: 61225 mg/mL
Sources:
unknown, adult and children
n = 2074
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 2074
Sources:
Adverse event 8 patients
775 mg/mL single, intravenous
Dose: 775 mg/mL
Route: intravenous
Route: single
Dose: 775 mg/mL
Sources:
unknown, adult and children
n = 1851
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 1851
Sources:
Adverse event 26 patients
775 mg/mL single, intravenous
Dose: 775 mg/mL
Route: intravenous
Route: single
Dose: 775 mg/mL
Sources:
unknown, adult and children
n = 2074
Health Status: unknown
Condition: computed tomography
Age Group: adult and children
Sex: unknown
Population Size: 2074
Sources:
PubMed

PubMed

TitleDatePubMed
[Iotrolan versus iopamidol. A controlled double-blind study with lumbar myelography].
1992 Aug
The role of early radiological studies after gastric bariatric surgery.
2001 Aug
Selective nerve root blocks for the treatment of sciatica: evaluation of injection site and effectiveness--a study with patients and cadavers.
2001 Dec
Ionic and non-ionic contrast agent-mediated endothelial injury. Quantitative analysis of cell proliferation during endothelial repair.
2001 Jul
Comparison of effects of ioxaglate versus iomeprol on histamine and tryptase release in patients with ischemic cardiomyopathy.
2001 Jul 15
[Severe thrombocytopenia induced by radiographic non-ionic contrast medium].
2001 Jun
Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis.
2001 Jun
Assessment of Fallopian tube patency by HyCoSy: comparison of a positive contrast agent with saline solution.
2001 Nov
Effects of hematocrit and blood flow distribution on solute clearance in hollow-fiber hemodialyzers.
2001 Nov
Differential effects of radiocontrast agents on human umbilical vein endothelial cells: cytotoxicity and modulators of thrombogenicity.
2001 Nov 20
[Doppler evaluation of thyroid hemodynamics after intravenous administration of contrast media].
2001 Nov-Dec
Is a routine liquid contrast swallow following laparoscopic gastric banding mandatory?
2001 Oct
Diagnostic accuracy of computed tomography for cervical metastases at different anatomical levels in carcinoma of the tongue.
2001 Sep
Fast 3D dynamic MR imaging of the liver with MR SmartPrep: comparison with helical CT in detecting hypervascular hepatocellular carcinoma.
2001 Sep-Oct
Pericaval fat collection mimicking an intracaval lesion on CT in patients with chronic liver disease.
2001 Sep-Oct
Acute occlusion of coronary artery bypass graft with nonionic contrast medium.
2002 Apr
Usefulness of multislice computed tomography for detecting obstructive coronary artery disease.
2002 Apr 15
Enhanced radio sensitivity with iodinated contrast agents using monochromatic synchrotron X-rays on human cancerous cells.
2002 Aug
Optimization of contrast agent administration in MSCT angiography.
2002 Aug
cAMP and cGMP do not mediate the vasorelaxation induced by iodinated radiographic contrast media in isolated swine renal arteries.
2002 Jan
[Value of triple phase helical CT for the detection of hepatocellular carcinoma in cirrhotic liver].
2002 Jan
Toxic epidermal necrolysis incriminating iopamidol in a child after cardiac catheterization.
2002 Jan
[Method of injection of contrast medium for brain perfusion CT].
2002 Jul
Optimum iodine concentration of contrast material through microcatheters: hydrodynamic analysis of experimental results.
2002 Jul 21
Iodinated contrast medium-induced potassium release: the effect of mixing ratios.
2002 Jul-Aug
Effects of iodinated contrast and field strength on gadolinium enhancement: implications for direct MR arthrography.
2002 Mar
New RES-specific contrast agents for CT.
2002 May
[Prospects of the use of non-ionic X-ray contrast media during endoscopic retrograde cholangiopancreatography].
2002 Nov-Dec
Aortic and hepatic enhancement and tumor-to-liver contrast: analysis of the effect of different concentrations of contrast material at multi-detector row helical CT.
2002 Sep
[CO2 angiography of transplanted kidneys].
2003
Effects of contrast media on erythrocyte aggregation during sedimentation.
2003 Apr
Ozonation: a tool for removal of pharmaceuticals, contrast media and musk fragrances from wastewater?
2003 Apr
Roles of intracellular Ca2+ and cyclic AMP in mast cell histamine release induced by radiographic contrast media.
2003 Apr
Nephrotoxicity of iopamidol in pediatric, adolescent, and young adult patients who have undergone allogeneic bone marrow transplantation.
2003 Feb
Visualization of breast lymphatic pathways with an indirect computed tomography lymphography using a nonionic monometric contrast medium iopamidol: preliminary results.
2003 Feb
Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial.
2003 Feb 5
Usefulness of electron beam tomography in the prone position for detecting atrial thrombi in chronic atrial fibrillation.
2003 Jan-Feb
[Successful use of transvenous angio-multidetector-CT in diagnosing cecal angiodysplasia as the cause of peranal hemorrhage].
2003 Jun
[Feasibility and optimization of the combined injection of contrast medium and normal saline with a single-syringe CT injection system].
2003 Jun
Three-dimensional CT angiography of the hepatic artery: use of multi-detector row helical CT and a contrast agent.
2003 Jun
Nonionic contrast media are less nephrotoxic than ionic contrast media to rat renal cortical slices.
2003 Jun 5
Delayed side effects induced by iodinated contrast media, especially those associated with iodixanol.
2003 Mar
Assessment of pancreatic CT enhancement using a high concentration of contrast material.
2003 Mar-Apr
Sonographic versus magnetic resonance arthrographic evaluation of full-thickness rotator cuff tears in millimeters.
2003 Mar-Apr
Simultaneous voiding cystourethrography and voiding urosonography.
2003 May
Cartilage lesions in the ankle joint: comparison of MR arthrography and CT arthrography.
2003 May
CT arthrography of the glenohumeral joint: CT fluoroscopy versus conventional CT and fluoroscopy--comparison of image-guidance techniques.
2003 Oct
Assessment of small bowel Crohn disease: noninvasive peroral CT enterography compared with other imaging methods and endoscopy--feasibility study.
2003 Oct
Fate of pharmaceuticals--photodegradation by simulated solar UV-light.
2003 Sep
Effect of contrast injection protocol with dose tailored to patient weight and fixed injection duration on aortic and hepatic enhancement at multidetector-row helical CT.
2003 Sep
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Dosage and administration depends on analysis type, patient age and contrast agent concentration. ISOVUE is available in different concentrations: 128, 200, 250, 300 and 370 mgI/ml.
Peripheral Arteriograghy: For injection into the femoral artery or subclavian artery, 5 to 40 mL of ISOVUE-300 may be used; for injection into the aorta for a distal runoff, 25 to 50 mL may be used. Doses up to a total of 250 mL of ISOVUE-300 have been administered during peripheral arteriography.
Route of Administration: Intravascular
In Vitro Use Guide
Curator's Comment:: Iopamidol increases the clotting time. http://www.ncbi.nlm.nih.gov/pubmed/2745021
Diffusion of iopamidol (300 and 200 mgI/ml) was studied in the cerebrospinal fluid (CSF). Test tubes containing CSF were kept in a waterbath at 37 degrees C. Contrast medium was injected along the wall into the tubes, and diffusion of contrast media in the tubes was followed with repeated computed tomography for 5 h. The contents of the tubes were then mixed by shaking, and the tubes were scanned immediately and 8 h later.
Name Type Language
IOPAMIDOL
EP   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
IOPAMIDOL [ORANGE BOOK]
Common Name English
IOPAMIDOL [EP MONOGRAPH]
Common Name English
IOPAMIDOL [USAN]
Common Name English
IOPAMIDOL [WHO-DD]
Common Name English
IOPAMIDOL [VANDF]
Common Name English
SQ-13396
Code English
(S)-N,N'-BIS(2-HYDROXY-1-(HYDROXYMETHYL)ETHYL)-2,4,6-TRIIODO-5-LACTAMIDOISOPHTHALAMIDE
Systematic Name English
IOPAMIDOL [USP MONOGRAPH]
Common Name English
1,3-BENZENEDICARBOXAMIDE, N,N'-BIS(2-HYDROXY-1-(HYDROXYMETHYL)ETHYL)-5-((2-HYDROXY-1-OXOPROPYL)AMINO)-2,4,6-TRIIODO-, (S)-
Common Name English
ISOVUE
Brand Name English
IOPAMIDOL [INN]
Common Name English
IOPAMIDOL [EP]
Common Name English
SQ 13,396
Code English
IOPAMIDOL [MI]
Common Name English
IOPAMIRON
Brand Name English
IOPAMIDOL [MART.]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C28500
Created by admin on Fri Jun 25 21:05:47 UTC 2021 , Edited by admin on Fri Jun 25 21:05:47 UTC 2021
WHO-VATC QV08AB04
Created by admin on Fri Jun 25 21:05:47 UTC 2021 , Edited by admin on Fri Jun 25 21:05:47 UTC 2021
WHO-ATC V08AB04
Created by admin on Fri Jun 25 21:05:47 UTC 2021 , Edited by admin on Fri Jun 25 21:05:47 UTC 2021
NDF-RT N0000010258
Created by admin on Fri Jun 25 21:05:47 UTC 2021 , Edited by admin on Fri Jun 25 21:05:47 UTC 2021
NDF-RT N0000180185
Created by admin on Fri Jun 25 21:05:47 UTC 2021 , Edited by admin on Fri Jun 25 21:05:47 UTC 2021
Code System Code Type Description
DRUG CENTRAL
1464
Created by admin on Fri Jun 25 21:05:47 UTC 2021 , Edited by admin on Fri Jun 25 21:05:47 UTC 2021
PRIMARY
WIKIPEDIA
IOPAMIDOL
Created by admin on Fri Jun 25 21:05:47 UTC 2021 , Edited by admin on Fri Jun 25 21:05:47 UTC 2021
PRIMARY
ChEMBL
CHEMBL1200932
Created by admin on Fri Jun 25 21:05:47 UTC 2021 , Edited by admin on Fri Jun 25 21:05:47 UTC 2021
PRIMARY
CAS
60166-93-0
Created by admin on Fri Jun 25 21:05:47 UTC 2021 , Edited by admin on Fri Jun 25 21:05:47 UTC 2021
PRIMARY
MESH
D007479
Created by admin on Fri Jun 25 21:05:47 UTC 2021 , Edited by admin on Fri Jun 25 21:05:47 UTC 2021
PRIMARY
ECHA (EC/EINECS)
262-093-6
Created by admin on Fri Jun 25 21:05:47 UTC 2021 , Edited by admin on Fri Jun 25 21:05:47 UTC 2021
PRIMARY
EVMPD
SUB08239MIG
Created by admin on Fri Jun 25 21:05:47 UTC 2021 , Edited by admin on Fri Jun 25 21:05:47 UTC 2021
PRIMARY
MERCK INDEX
M6370
Created by admin on Fri Jun 25 21:05:47 UTC 2021 , Edited by admin on Fri Jun 25 21:05:47 UTC 2021
PRIMARY Merck Index
PUBCHEM
65492
Created by admin on Fri Jun 25 21:05:47 UTC 2021 , Edited by admin on Fri Jun 25 21:05:47 UTC 2021
PRIMARY
HSDB
8075
Created by admin on Fri Jun 25 21:05:47 UTC 2021 , Edited by admin on Fri Jun 25 21:05:47 UTC 2021
PRIMARY
NCI_THESAURUS
C47567
Created by admin on Fri Jun 25 21:05:47 UTC 2021 , Edited by admin on Fri Jun 25 21:05:47 UTC 2021
PRIMARY
LACTMED
Iopamidol
Created by admin on Fri Jun 25 21:05:47 UTC 2021 , Edited by admin on Fri Jun 25 21:05:47 UTC 2021
PRIMARY
USP_CATALOG
1344702
Created by admin on Fri Jun 25 21:05:47 UTC 2021 , Edited by admin on Fri Jun 25 21:05:47 UTC 2021
PRIMARY USP-RS
DRUG BANK
DB08947
Created by admin on Fri Jun 25 21:05:47 UTC 2021 , Edited by admin on Fri Jun 25 21:05:47 UTC 2021
PRIMARY
FDA UNII
JR13W81H44
Created by admin on Fri Jun 25 21:05:47 UTC 2021 , Edited by admin on Fri Jun 25 21:05:47 UTC 2021
PRIMARY
EPA CompTox
60166-93-0
Created by admin on Fri Jun 25 21:05:47 UTC 2021 , Edited by admin on Fri Jun 25 21:05:47 UTC 2021
PRIMARY
INN
4399
Created by admin on Fri Jun 25 21:05:47 UTC 2021 , Edited by admin on Fri Jun 25 21:05:47 UTC 2021
PRIMARY
RXCUI
5966
Created by admin on Fri Jun 25 21:05:47 UTC 2021 , Edited by admin on Fri Jun 25 21:05:47 UTC 2021
PRIMARY RxNorm